The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|5|907-917

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.5, 2013-02, pp. : 907-917

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting hypoxia-inducible factor-1 for therapy and prevention

By Zhong Hua  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 7, 2004-07 ,pp. : 951-966

Informa Healthcare

Access to resources Recommend Favorite

Cancer Therapy By Targeting Hypoxia-Inducible Factor-1

By  

Current Cancer Drug Targets, Vol. 10, Iss. 7, 2010-11 ,pp. : 782-796

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor

By  

Current Drug Targets, Vol. 6, Iss. 3, 2005-05 ,pp. : 275-287

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

By  

Current Medicinal Chemistry, Vol. 18, Iss. 21, 2011-07 ,pp. : 3168-3189

Bentham Science Publishers

Access to resources Recommend Favorite

Sales of human epidermal growth factor receptor 2 (HER2)-targeting breast cancer therapies are set to grow by 3.3% per annum

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 592, 2009-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite